Success Metrics

Clinical Success Rate

75.0%

Based on 6 completed trials

Completion Rate

75%(6/8)

Active Trials

0(0%)

Results Posted

33%(2 trials)

Terminated

2(22%)

Phase Distribution

Ph phase_1

56%

Ph phase_2

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

5(55.6%)

Phase 2Efficacy & side effects

4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

6 of 9 finished

Non-Completion Rate

33.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Terminated(3)

Detailed Status

Completed6

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Phase 15 (55.6%)

Phase 24 (44.4%)

Trials by Status

withdrawn111%

completed667%

terminated222%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_1

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

NCT02279719

terminatedphase_2

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

NCT02432690

completedphase_1

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

NCT01781455

terminatedphase_2

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

NCT02232620

completedphase_2

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

NCT02232633

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT02279719Phase 1

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Completed

NCT02432690Phase 2

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

Terminated

NCT01781455Phase 1

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

Completed

NCT02232620Phase 2

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Terminated

NCT02232633Phase 2

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Completed

NCT02232646Phase 2

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Withdrawn

NCT02483247Phase 1

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

Completed

NCT02432326Phase 1

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Completed

NCT02354898Phase 1

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9